News

Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)

Richmond, Va – Kaléo, a privately held U.S. pharmaceutical company, today announced that

it has entered into a ten-year License, Supply, and Commercialization agreement with Valeo Pharma, a

Canadian pharmaceutical company, for the Canadian rights to ALLERJECT® (epinephrine injection, USP) for the

treatment of severe allergic reactions.

“Patients with life threatening allergies across Canada deserve access to this innovative and potentially

lifesaving product,” said Kaléo President and CEO Ronald Gunn. “Valeo Pharma’s sales force, relationships with

the healthcare community, and commitment to patients make them the ideal partner for ALLERJECT.”

For more information please click here.

Recent News

01/21/2025

MicroAire Completes Acquisition of NEOSYAD

MicroAire Surgical Instruments, the global leader in power-assisted liposuction, is pleased to announce the acquisition of NEOSYAD, an innovative medical device company that developed a breakthrough technology for adipose tissue engineering. This strategic move reinforces MicroAire’s commitment to advancing medical innovation and strengthening its leadership in the adipose tissue market. NEOSYAD recently received EU MDR

01/17/2025

ATCC Appoints Dr. Ruth Cheng as New President and Chief Executive Officer

ATCC, the world’s premier biological materials management and standards organization, today announced the appointment of Ruth Cheng, PhD, as president and chief executive officer. Dr. Cheng, who has been with ATCC for five years and most recently served as senior vice president and general manager, Research and Industrial Solutions, succeeds Raymond H. Cypess, DVM, PhD, who

01/15/2025

Alliance for Building Better Medicine Partners Secure $3.94 Million Federal Grant to Strengthen Richmond-Petersburg Region’s Pharma and Biotech Workforce and Talent System

Under the leadership of Alliance-member organization J. Sargeant Reynolds Community College (Reynolds), the Alliance for Building Better Medicine has secured a landmark $3.94 million federal grant through the U.S. Economic Development Administration’s (EDA) Good Jobs Challenge Award. The funding will support the Richmond-Petersburg Advanced Pharmaceutical Manufacturing (APM) Workforce Initiative. This transformative project, led by Reynolds